Nurix Therapeutics (NRIX) Breaks 200‑Day Trend, Gains 4.7% in Volatile Biotech Market
Nurix Therapeutics (NRIX) climbs 4.69%, driven by a protein‑control platform that promises to tackle “undruggable” diseases—investors weigh upside against trial risks.
- NURIX THERAPEUTICS INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read